First Time Loading...

Marinus Pharmaceuticals Inc
NASDAQ:MRNS

Watchlist Manager
Marinus Pharmaceuticals Inc Logo
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Watchlist
Price: 1.48 USD -1.99% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one MRNS stock under the Base Case scenario is 7.19 USD. Compared to the current market price of 1.48 USD, Marinus Pharmaceuticals Inc is Undervalued by 79%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRNS Relative Value
Base Case
7.19 USD
Undervaluation 79%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
68
vs Industry
43
Median 3Y
15.8
Median 5Y
12.9
Industry
2.5
Forward
2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5
Median 5Y
-4.4
Industry
23.4
Forward
-0.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-4.2
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.3
Industry
23.6
More Details
4.8
P/B
P/B
Price to Book Value
4.8
vs History
46
vs Industry
14
Median 3Y
5.6
Median 5Y
4.7
Industry
2.1
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
92
Median 3Y
10.7
Median 5Y
8.1
Industry
2.6
Forward
-0.2
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
88
Median 3Y
8.1
Median 5Y
0
Industry
5.2
More Details
0.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.1
vs History
1
vs Industry
56
Median 3Y
-2.5
Median 5Y
-2.5
Industry
13.7
More Details
0.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.1
vs History
1
vs Industry
53
Median 3Y
-2.5
Median 5Y
-2.5
Industry
17.2
Forward
0.1
More Details
0.1
EV/OCF
EV/OCF
Enterprise Value to OCF
0.1
vs History
1
vs Industry
55
Median 3Y
-2.9
Median 5Y
-2.9
Industry
16.2
More Details
0.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.1
vs History
1
vs Industry
42
Median 3Y
-2.9
Median 5Y
-2.9
Industry
17.8
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
83
Median 3Y
18.5
Median 5Y
21.7
Industry
2
More Details

Multiples Across Competitors

MRNS Competitors Multiples
Marinus Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
80.8m USD 2.6 -0.6 0.1 0.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
728.7B USD 20.3 118.7 58.1 66.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.7 46.4 34 37
US
Johnson & Johnson
NYSE:JNJ
357.6B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
323.1B USD 5.3 140.1 34.9 57
UK
AstraZeneca PLC
LSE:AZN
187.2B GBP 4.9 37.2 174.3 278
CH
Novartis AG
SIX:NOVN
182.7B CHF 4.3 13.6 9.9 16.4
CH
Roche Holding AG
SIX:ROG
175.4B CHF 3 15.3 8.7 10.3
US
Pfizer Inc
NYSE:PFE
159B USD 2.9 -514.5 12.8 20.3
P/E Multiple
Earnings Growth
US
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Average P/E: 54.4
Negative Multiple: -0.6 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.7
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
46.4
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
140.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.2
168%
CH
Novartis AG
SIX:NOVN
13.6
15%
CH
Roche Holding AG
SIX:ROG
15.3
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -514.5
680%

See Also

Summary
MRNS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRNS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRNS stock valuation using valuation multiples.
Wall Street Estimates
MRNS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRNS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.